e-learning
resources
Milan 2017
Monday, 11.09.2017
Cystic fibrosis: treatments and monitoring
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Examining the effects of the Gly551Asp mutation on CT outcomes in children with cystic fibrosis
L. Mok (Perth, WA, Australia)
Source:
International Congress 2017 – Cystic fibrosis: treatments and monitoring
Session:
Cystic fibrosis: treatments and monitoring
Session type:
Poster Discussion
Number:
1830
Disease area:
Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Mok (Perth, WA, Australia). Examining the effects of the Gly551Asp mutation on CT outcomes in children with cystic fibrosis. 1830
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Imaging of eosinophilic lung disease
Cystic fibrosis and intestinal organoids
Related content which might interest you:
The effect of CFTR modulators on CT outcomes in cystic fibrosis
Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Year: 2019
High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and ΔF508
Source: Eur Respir J 2001; 17: 1181-1186
Year: 2001
Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation
Source: Eur Respir J 2016; 47:1697-1705
Year: 2016
Should the D1152H variant be included in cystic fibrosis newborn screening programmes?
Source: Virtual Congress 2020 – Cystic fibrosis
Year: 2020
Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients
Source: Eur Respir J 2004; 23: 679-684
Year: 2004
Morbidity and mortality in carriers of the cystic fibrosis mutation
CFTR
Phe508del in the general population
Source: Eur Respir J, 56 (3) 2000558; 10.1183/13993003.00558-2020
Year: 2020
A novel
CFTR
mutation found in a Chinese cystic fibrosis patient
Source: Eur Respir J 2005; 26: Suppl. 49, 402s
Year: 2005
Distinctive CFTR gene mutations found in Japanese individuals with cystic fibrosis
Source: Annual Congress 2004 - Cystic fibrosis in the 21
st
century: cutting edge investigations, taxing problems
Year: 2004
Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018
Progression of lung disease detected by MRI and impact of NBS in preschool children with cystic fibrosis
Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Year: 2019
CFTR gene mutations detected in Japanese individuals with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 716s
Year: 2006
Characteristics of cystic fibrosis patients diagnosed after false negative cystic fibrosis newborn screening results
Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis
Year: 2019
The impact of genotype on clinical course of cystic fibrosis (CF) in adult patients
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
Clinical characteristics and disease severity of adults with cystic fibrosis with at least one residual function mutation
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018
Polysomnograpgic findings in children with cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 391s
Year: 2003
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019
Year: 2020
Potentiating and correcting mutant CFTR in patients with cystic fibrosis
Source: Eur Respir Monogr 2014; 64: 129-149
Year: 2014
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two
F508del
alleles
Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019
Year: 2019
First identified “severe” mutations and extended rearrangements in the CFTR gene in Russian cystic fibrosis patients
Source: Virtual Congress 2020 – Cystic fibrosis
Year: 2020
Real life experience of lumacaftor/ivacafotor in adult Phe508del homozygous cystic fibrosis patients.
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept